Why the study?
Does high-dose atorvastatin reduce major coronary events compared to usual-dose simvastatin in patients with previous myocardial infarction?
Does high-dose atorvastatin reduce major coronary events compared to usual-dose simvastatin in patients with previous myocardial infarction?
In patients with previous MI, high-dose atorvastatin did not significantly reduce major coronary events compared to usual-dose simvastatin, but did reduce nonfatal acute MI without increasing serious adverse reactions.
Answers are grounded in this paper and cite their sources.
High-dose atorvastatin does not reduce major coronary events versus usual-dose simvastatin post-MI; challenges routine statin intensification despite secondary benefits.
In this study of patients with previous MI, intensive lowering of LDL-C did not result in a significant reduction in the primary outcome of major coronary events, but did reduce the risk of other composite secondary end points and nonfatal acute MI. There were no differences in cardiovascular or all-cause mortality. Patients with MI may benefit from intensive lowering of LDL-C without an increase in noncardiovascular mortality or other serious adverse reactions.Trial Registration ClinicalTrials.gov Identifier: NCT00159835.
No takes yet. Share an insight, caveat, or question.
Terje R. Pedersen (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: